DK2969099T4 - Fjernelse af lækket affinitetsoprensningsligand - Google Patents

Fjernelse af lækket affinitetsoprensningsligand Download PDF

Info

Publication number
DK2969099T4
DK2969099T4 DK14714890.2T DK14714890T DK2969099T4 DK 2969099 T4 DK2969099 T4 DK 2969099T4 DK 14714890 T DK14714890 T DK 14714890T DK 2969099 T4 DK2969099 T4 DK 2969099T4
Authority
DK
Denmark
Prior art keywords
leaked
removal
affinity purification
purification ligand
ligand
Prior art date
Application number
DK14714890.2T
Other languages
Danish (da)
English (en)
Other versions
DK2969099T3 (en
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2969099(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2969099T3 publication Critical patent/DK2969099T3/en
Publication of DK2969099T4 publication Critical patent/DK2969099T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14714890.2T 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand DK2969099T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (2)

Publication Number Publication Date
DK2969099T3 DK2969099T3 (en) 2018-07-09
DK2969099T4 true DK2969099T4 (da) 2022-03-14

Family

ID=50424772

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14714890.2T DK2969099T4 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand
DK18168494.5T DK3395423T3 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18168494.5T DK3395423T3 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand

Country Status (17)

Country Link
US (3) US20160024144A1 (enExample)
EP (3) EP4026596A1 (enExample)
JP (1) JP6457479B2 (enExample)
AU (1) AU2014240596B2 (enExample)
CA (1) CA2904411A1 (enExample)
CY (1) CY1120353T1 (enExample)
DK (2) DK2969099T4 (enExample)
ES (2) ES2964601T3 (enExample)
FI (1) FI3395423T3 (enExample)
HU (2) HUE064450T2 (enExample)
LT (2) LT3395423T (enExample)
MX (2) MX365501B (enExample)
PL (2) PL3395423T3 (enExample)
PT (2) PT3395423T (enExample)
SI (2) SI2969099T2 (enExample)
TR (1) TR201809050T4 (enExample)
WO (1) WO2014159441A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2015189832A1 (en) * 2014-06-13 2015-12-17 Lupin Limited Process for the purification of tnfr:fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
CA2225378C (en) 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0991940B1 (de) 1997-06-18 2010-08-25 Merck Patent GmbH Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
JP4363986B2 (ja) * 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
BRPI0608584B8 (pt) * 2005-03-11 2021-05-25 Wyeth Corp métodos de recuperar um produto purificado
CN102391358B (zh) * 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
MX2009004974A (es) * 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
CA2932207A1 (en) * 2008-10-20 2010-12-09 Abbvie Inc. Isolation and purification of antibodies using protein a affinity chromatography
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
US9428546B2 (en) * 2010-07-30 2016-08-30 Pfizer Inc. Tandem purification of proteins
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
JP6280499B2 (ja) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
US9574010B2 (en) * 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
PL3395423T3 (pl) 2013-03-14 2024-03-18 Amgen Inc. Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa

Also Published As

Publication number Publication date
PL2969099T5 (pl) 2022-06-13
WO2014159441A1 (en) 2014-10-02
MX391507B (es) 2025-03-21
MX2015011994A (es) 2015-12-01
SI2969099T1 (sl) 2018-09-28
HUE038565T2 (hu) 2018-10-29
ES2674697T3 (es) 2018-07-03
LT2969099T (lt) 2018-09-10
US11192919B2 (en) 2021-12-07
US20190085021A1 (en) 2019-03-21
DK2969099T3 (en) 2018-07-09
US20160024144A1 (en) 2016-01-28
PT3395423T (pt) 2023-11-14
FI3395423T3 (fi) 2023-11-02
ES2674697T5 (es) 2022-04-19
JP6457479B2 (ja) 2019-01-23
EP2969099A1 (en) 2016-01-20
JP2016513643A (ja) 2016-05-16
SI2969099T2 (sl) 2022-04-29
US20220144886A1 (en) 2022-05-12
SI3395423T1 (sl) 2023-12-29
HK1220159A1 (en) 2017-04-28
US11492372B2 (en) 2022-11-08
EP4026596A1 (en) 2022-07-13
EP2969099B2 (en) 2021-12-22
AU2014240596B2 (en) 2018-09-27
EP3395423A1 (en) 2018-10-31
HUE064450T2 (hu) 2024-03-28
TR201809050T4 (tr) 2018-07-23
MX2019006568A (es) 2019-08-22
MX365501B (es) 2019-06-05
PL2969099T3 (pl) 2018-10-31
PT2969099T (pt) 2018-07-05
CA2904411A1 (en) 2014-10-02
PL3395423T3 (pl) 2024-03-18
EP2969099B1 (en) 2018-04-25
AU2014240596A1 (en) 2015-09-24
EP3395423B1 (en) 2023-09-20
DK3395423T3 (da) 2023-11-20
LT3395423T (lt) 2023-12-11
CY1120353T1 (el) 2019-07-10
ES2964601T3 (es) 2024-04-08

Similar Documents

Publication Publication Date Title
FIC20240024I1 (fi) Lutetium (177Lu) vipivotiditetraksetaani
DK2970954T3 (da) Modifikation af polypeptider
DK2968208T3 (da) Behandling af kataplexi
BR112015019232A2 (pt) filtração
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3043827T3 (da) Modulatorer af komplement faktor b
DK3068854T3 (da) Fjernelse af uønskede propanolkomponenter
DK2961388T3 (da) Kombinationer af lægemidler
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3063264T3 (da) Tørring af mikroorganismer
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
EP2982134A4 (en) AUDIO FILTER WITH SINUS FUNCTIONS
DK2991543T3 (da) System til visualisering af kropsområder
DK3395423T3 (da) Fjernelse af lækket affinitetsoprensningsligand
EP2948557A4 (en) CLEANING OF CADAVERIN
DK2822301T3 (da) Bestemmelse af individuelle HRTF
DE112014001869A5 (de) Bearbeitungszentrum
DK2838850T3 (da) Oprensning af titantetrachlorid
PL2765250T3 (pl) Rynna odpływowa
DK3080574T3 (da) Overvågning af ringvolumen
TH1301002962B (th) ตัวดูดซับสำหรับการกำจัดคลอไรด์
TH1501000312A (th) ตัวกรอง
UA28681S (uk) Фільтр масляний
UA25702S (uk) Фільтр масляний
UA25836S (uk) Фільтр масляний